U.S. Equities1h ago
Eli Lilly's Retatrutide Shows 20.8% Weight Loss at Top Dose; BLA Due Q1 2027
Triple agonist achieves dose-dependent weight reductions up to 49.6 pounds and A1C drops to 5.7% in 40% of patients, clearing path for 2027 market entry.